Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.39 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.39 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ST6GAL1 | P15907 | 4/20 | 0.37 |
| ▸ | NT5E | P21589 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.35 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.34 |
| ▸ | ALB | P02768 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.34 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL254556 | 1.00 | LMNA (0.39) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL12362212 | 1.00 | LMNA (0.39) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL19519593 | 1.00 | LMNA (0.39) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL10034041 | 1.00 | LMNA (0.39) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL14817354 | 0.84 | POLB (0.34) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL5557391 | 0.82 | LMNA (0.52) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL2767893 | 0.82 | LMNA (0.52) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL1097293 | 0.82 | LMNA (0.52) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL19259067 | 0.82 | LMNA (0.52) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL15677983 | 0.79 | POLG (0.53) | POLBP2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10391166-B2 | Short oligonucleotides as vaccine adjuvants and therapeutic agents | SPRING BREAK PHARMACEUTICALS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10391166-B2 | Short oligonucleotides as vaccine adjuvants and therapeutic agents | TLR3, TLR5, TLR9 | LMNA 3914/4885THRB 3399/4885MTOR 2460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.